Abstracts tagged "Myositis"

Abstract Number: 1262 • 2014 ACR/ARHP Annual Meeting
Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto-Antibodies
Yves Allenbach^1,2,3, Aude Rigolet³, Bruno Eymard⁴, Tanya Stojkovic⁴, Anthony. Behin⁴, Pascal Laforet⁴, Peter Hufnagl⁵, Norman Zerbe⁶, Thierry Maisonobe⁷, Kuberaka Mariampillai⁸, Serge Herson⁸, Olivier Benveniste^2,3 and Werner Stenzel⁹, ¹Neuropathology, Charite Hospital, Berlin, Germany, ²UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ³Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁵Pathology departmen, Charite Hospital, Berlin, Germany, ⁶Department of Pathology, Charite Hospital, Berlin, Germany, ⁷Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ⁸Department: inflammation, immunopathology and biotherapy (DHU i2B), Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁹Department of Neuropathology, Charite Hospital, Berlin, Germany
Background/Purpose: Necrotizing auto-immune myopathies (NAM) are a group of acquired idiopathic inflammatory myopathies characterized by severe muscle weakness and no or mild extra-muscular involvement. Definition of…
Abstract Number: 1269 • 2014 ACR/ARHP Annual Meeting
Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique
Christophe Deligny¹, Maryvonne Dueymes², Serge Arfi¹, José Zécler³, Maia Forgues⁴, Véronique Dehlinger⁵, Michel DeBandt⁶, Lauren Brunier-Agot⁶, Remi Bellance⁷, Isabelle Lamaury⁸, Nadege Cordel⁸, Nicolas Baillet⁹, Gilbert. Cadelis¹⁰, Georges Jean Baptiste¹¹ and Katlyne Polomat¹², ¹Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ²Immunology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, ³Respiratory, Centre Hospitalier Universitaire de Fort de France, Fort de France, Martinique, ⁴Internal medicine, Centre Hospitalier Andre Rosemon, Cayenne, French Guiana, ⁵Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort De France - Martinique, Martinique, ⁶Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁷National center for rare neuromuscular disorders, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁸Infectious diseases, dermatology and internal medicine, Centre Hospitalier universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, ⁹internal medicine, Centre Hospitalier de la Basse Terre, Basse Terre, Guadeloupe, ¹⁰Respiratory, Cnetre Hospitalier Universitaire de Guadeloupe, Pointe à Pitre, Guadeloupe, ¹¹Rheumatology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Guadeloupe, ¹²Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique
Background/Purpose : There is no population based epidemiologic studies of antisynthetase syndrome (ASS). We described characteristics and epidemiology of this disease in Martinique, populated by…
Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Mikaela Chase¹, Anna Jansen¹, Karen Malley², Jesse Wilkerson³, Kathryn Rose⁴, Caroll Co⁴, Lukasz Itert⁵, Anne Johnson⁶, Richard Morris⁴, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁸, Frederick W. Miller¹, Bob Goldberg⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Malley Research Programming, Inc, Bethesda, MD, ³Social and Scientific Systems, Inc., Research Triangle Park, NC, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹The Myositis Association, Alexandria, VA
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…
Abstract Number: 2216 • 2014 ACR/ARHP Annual Meeting
Muscle Type I Interferon Gene Expression May Predict Therapeutic Responses to Rituximab in Myositis Patients
Kanneboyina Nagaraju^1,2, Svetlana Ghimbovschi³, Sree Rayavarapu^2,4, Aditi Phadke⁴, Lisa G Rider⁵, Eric Hoffman^2,4 and Frederick W. Miller⁶, ¹Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ²Department of Integrative Systems Biology, The George Washington University, Washington, DC, ³Research Center for Genetic Medicine, Children's National Medical Center, Washington DC, WA, ⁴Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, ⁵Environmental Autoimmunity Group, Program of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, ⁶Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD
Background/Purpose To identify muscle gene expression patterns that predict rituximab responses and assess the effects of rituximab on muscle gene expression in polymyositis (PM) and…
Abstract Number: 2222 • 2014 ACR/ARHP Annual Meeting
Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Jesse Wilkerson², Nastaran Bayat¹, Anna Jansen³, Kathryn Rose⁴, Lukasz Itert⁵, Anne Johnson⁶, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁹, Bob Goldberg¹⁰, Richard Morris⁴, Frederick W. Miller¹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Social and Scientific Systems, Inc., Research Triangle Park, NC, ³Environmental Autoimmunity Group, NIEHS / EAG, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹PRCSG, Cincinnati, OH, ¹⁰The Myositis Association, Alexandria, VA
Background/Purpose: Little is known about medications received for myositis and patients’ responses to therapies. We present information on self-reported myositis therapy use and responses from…
Abstract Number: 2227 • 2014 ACR/ARHP Annual Meeting
Physical Impairment in Patients with Idiopathic Inflammatory Myopathies Is Predicted By the American College of Rheumatology Functional Status Measure
Laura Cleary¹, Leslie J. Crofford², Archana Srinivas¹, Heather Bush¹, Catherine Starnes¹, Qian Fan¹, Jidan Duan¹, Kirk Jenkins¹, Natasha Fraser¹, Matthew Rutledge¹ and Beatriz Hanaoka³, ¹University of Kentucky, Lexington, KY, ²Div of Rheumatology & Immunology, Vanderbilt University, Nashville, TN, ³Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose The American College of Rheumatology classification criteria of functional status (ACR-FS) in Rheumatoid Arthritis is used as a measure of the consequences of impairment…
Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting
The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
I.M. Markusse¹, J. Meijs², B. de Boer², A. a. Schouffoer¹, N. Ajmone Marsan³, L. J. M. Kroft⁴, M. K. Ninaber⁵, T. W. J. Huizinga² and J.K. de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…
Abstract Number: 1936 • 2013 ACR/ARHP Annual Meeting
Quality Of Care In Patients At Risk For Pulmonary Involvement: Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic
Michael G. Indelicato¹, Janet E. Lewis², Vincent J. Giuliano³ and Donald L. Kimpel⁴, ¹Rheumatology, University of Virginia, Charlottesville, VA, ²Rheumatology, University of Virginia School of Medicine, Charlottesville, VA, ³University of Virginia, Charlottesville, VA, ⁴Rheumatology and Immunology, University of Virginia School of Medicine, Charlottesville, VA
Background/Purpose: As a quality assessment tool to evaluate patient care in a general Rheumatology Clinic, we determined the frequency of screening for pulmonary hypertension and…
Abstract Number: 1952 • 2012 ACR/ARHP Annual Meeting
The Effect of CXCL10 Blockade in C Protein-Induced Myositis
Jinhyun Kim¹, Jiyong Choi², Sung Hae Chang³, Ki Chul Shin⁴, Sung-Hye Park⁵, Hye Won Kim⁶, Hye Jin Oh⁴, Myeong Jae Yoon⁷, Bong Seung Ku⁸, Eun Young Lee⁶, Eun Bong Lee³, Hiroshi Kawachi⁹, Hitoshi Kohsaka¹⁰ and Yeong Wook Song¹¹, ¹Department of Internal medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁴Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ⁵Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁷Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, ⁸Rheumatology, Department of Internal Medicine, School of Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, South Korea, ⁹Department of Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ¹⁰Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: CXCL10 (also called interferon-γ-inducible protein 10 [IP-10]) is a chemokine that plays a critical role in the infiltration of T cell in autoimmune disease…
Abstract Number: 1928 • 2012 ACR/ARHP Annual Meeting
Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients
Ragnar Gunnarsson¹, Inge-Margrethe Gilboe¹, Torhild Garen² and Øyvind Molberg³, ¹Rheumatology unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway
Background/Purpose: Even though 40 years have passed since MCTD was defined as a distinct disorder, there is still no evidence based therapy available. The choice…
Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Kyle P. Chiang¹, Varun Gauba¹, Darin Lee¹, Minh-Ha T. Do¹, Jie J. Zhou², Feng Wang², Ying Buechler¹, Leslie Nangle¹, Zhiwen Xu², John Mendlein¹, Melissa Ashlock¹ and Jeffrey M. Greve¹, ¹aTyr Pharma, San Diego, CA, ²Scripps Laboratory, Institute for Advanced Study, Hong Kong University of Science and Technology, Kowloon, Hong Kong
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…
Abstract Number: 754 • 2012 ACR/ARHP Annual Meeting
The Functional Index-3 in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance
Christopher Chong¹, Orla Ni Mhuircheartaigh¹, Helene Alexanderson², Tanaz A. Kermani³, Cynthia S. Crowson⁴, Abigail B. Green⁴, Ann M. Reed⁵ and Floranne C. Ernste⁶, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Dept of Neuroscience, Care Science and Society, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Although muscle fatigue is a major source of functional impairment in dermatomyositis (DM) and polymyositis (PM), few valid and reliable methods for efficient evaluation…
Abstract Number: 711 • 2012 ACR/ARHP Annual Meeting
Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group
MIchelle Jung¹, Murray Baron², Marie Hudson³, Ashley Bonner⁴, Janet E. Pope⁵ and Canadian Scleroderma Research Group⁶, ¹Western University, London, ON, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Montreal, QC, Canada
Background/Purpose: Myopathy / myositis is associated with more severe systemic scleroderma (SSc). The aim of this study was to determine such clinical information from the…
Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Kavish J. Bhansing¹, Piet LCM Van Riel², Sigrid Pillen³, Baziel G.M. van Engelen⁴ and Madelon C. Vonk⁵, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Neurology, Catharina Wilhemina Hospital, Nijmegen, Netherlands, ⁴Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…
Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting
The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study
Pedro Machado¹, Andrea Cortese¹, Jasper Morrow¹, Liz Dewar¹, Andy Hiscock¹, Adrian Miller¹, Stefen Brady², David Hilton-Jones², Matt Parton¹ and Michael G. Hanna¹, ¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ²Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.